Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Highly conserved influenza T cell epitopes induce broadly protective immunity.

Eickhoff CS, Terry FE, Peng L, Meza KA, Sakala IG, Van Aartsen D, Moise L, Martin WD, Schriewer J, Buller RM, De Groot AS, Hoft DF.

Vaccine. 2019 Aug 23;37(36):5371-5381. doi: 10.1016/j.vaccine.2019.07.033. Epub 2019 Jul 19.

PMID:
31331771
2.

CCR5 is a required signaling receptor for macrophage expression of inflammatory genes in response to viral double-stranded RNA.

Shaheen ZR, Christmann BS, Stafford JD, Moran JM, Buller RML, Corbett JA.

Am J Physiol Regul Integr Comp Physiol. 2019 May 1;316(5):R525-R534. doi: 10.1152/ajpregu.00019.2019. Epub 2019 Feb 27.

PMID:
30811246
3.

Directed evolution of carbon-hydrogen bond activating enzymes.

Frey R, Hayashi T, Buller RM.

Curr Opin Biotechnol. 2018 Dec 21;60:29-38. doi: 10.1016/j.copbio.2018.12.004. [Epub ahead of print] Review.

PMID:
30583278
4.

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents.

Ananthula HK, Parker S, Touchette E, Buller RM, Patel G, Kalman D, Salzer JS, Gallardo-Romero N, Olson V, Damon IK, Moir-Savitz T, Sallans L, Werner MH, Sherwin CM, Desai PB.

BMC Pharmacol Toxicol. 2018 Dec 4;19(1):80. doi: 10.1186/s40360-018-0270-x.

5.

Identifying and Tracking Low-Frequency Virus-Specific TCR Clonotypes Using High-Throughput Sequencing.

Wolf K, Hether T, Gilchuk P, Kumar A, Rajeh A, Schiebout C, Maybruck J, Buller RM, Ahn TH, Joyce S, DiPaolo RJ.

Cell Rep. 2018 Nov 27;25(9):2369-2378.e4. doi: 10.1016/j.celrep.2018.11.009.

6.

The Virology of Taterapox Virus In Vitro.

Parker S, Camilo de Oliveira L, Lefkowitz EJ, Hendrickson RC, Bonjardim CA, Wold WSM, Hartzler H, Crump R, Buller RM.

Viruses. 2018 Aug 29;10(9). pii: E463. doi: 10.3390/v10090463.

7.

Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice.

Long KR, Lomonosova E, Li Q, Ponzar NL, Villa JA, Touchette E, Rapp S, Liley RM, Murelli RP, Grigoryan A, Buller RM, Wilson L, Bial J, Sagartz JE, Tavis JE.

Antiviral Res. 2018 Jan;149:41-47. doi: 10.1016/j.antiviral.2017.11.008. Epub 2017 Nov 10.

8.

Evaluation of Taterapox Virus in Small Animals.

Parker S, Crump R, Hartzler H, Buller RM.

Viruses. 2017 Aug 1;9(8). pii: E203. doi: 10.3390/v9080203.

9.

Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.

Crump R, Korom M, Buller RM, Parker S.

Antiviral Res. 2017 Mar;139:112-116. doi: 10.1016/j.antiviral.2016.12.015. Epub 2016 Dec 27.

10.

Conventional and Regulatory CD4+ T Cells That Share Identical TCRs Are Derived from Common Clones.

Wolf KJ, Emerson RO, Pingel J, Buller RM, DiPaolo RJ.

PLoS One. 2016 Apr 21;11(4):e0153705. doi: 10.1371/journal.pone.0153705. eCollection 2016.

11.

Evidence for Persistence of Ectromelia Virus in Inbred Mice, Recrudescence Following Immunosuppression and Transmission to Naïve Mice.

Sakala IG, Chaudhri G, Scalzo AA, Eldi P, Newsome TP, Buller RM, Karupiah G.

PLoS Pathog. 2015 Dec 23;11(12):e1005342. doi: 10.1371/journal.ppat.1005342. eCollection 2015 Dec.

12.

The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection.

Rapaport AS, Schriewer J, Gilfillan S, Hembrador E, Crump R, Plougastel BF, Wang Y, Le Friec G, Gao J, Cella M, Pircher H, Yokoyama WM, Buller RM, Colonna M.

Immunity. 2015 Dec 15;43(6):1112-24. doi: 10.1016/j.immuni.2015.11.005. Epub 2015 Dec 8.

13.

Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.

Kuruganti S, Miersch S, Deshpande A, Speir JA, Harris BD, Schriewer JM, Buller RM, Sidhu SS, Walter MR.

J Biol Chem. 2016 Jan 1;291(1):447-61. doi: 10.1074/jbc.M115.665943. Epub 2015 Nov 6.

14.

Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation.

Sei JJ, Haskett S, Kaminsky LW, Lin E, Truckenmiller ME, Bellone CJ, Buller RM, Norbury CC.

PLoS Pathog. 2015 Jun 24;11(6):e1004941. doi: 10.1371/journal.ppat.1004941. eCollection 2015 Jun.

15.

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity.

Napier RJ, Norris BA, Swimm A, Giver CR, Harris WA, Laval J, Napier BA, Patel G, Crump R, Peng Z, Bornmann W, Pulendran B, Buller RM, Weiss DS, Tirouvanziam R, Waller EK, Kalman D.

PLoS Pathog. 2015 Mar 30;11(3):e1004770. doi: 10.1371/journal.ppat.1004770. eCollection 2015 Mar.

16.

Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters.

Toth K, Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Sagartz JE, Buller RM, Wold WS.

Viruses. 2015 Mar 23;7(3):1409-28. doi: 10.3390/v7031409.

17.

Deficiency in Th2 cytokine responses exacerbate orthopoxvirus infection.

Sakala IG, Chaudhri G, Eldi P, Buller RM, Karupiah G.

PLoS One. 2015 Mar 9;10(3):e0118685. doi: 10.1371/journal.pone.0118685. eCollection 2015.

18.

Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.

Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K.

Antiviral Res. 2014 Dec;112:38-46. doi: 10.1016/j.antiviral.2014.10.005. Epub 2014 Oct 15.

PMID:
25453340
19.

Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.

Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Dewhurst S, Capella C, Buller RM, Toth K, Wold WS.

Antimicrob Agents Chemother. 2014 Dec;58(12):7171-81. doi: 10.1128/AAC.03860-14. Epub 2014 Sep 15.

20.

Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.

Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier ER, Painter G, Schriewer J, Trost LC, Buller RM.

Antiviral Res. 2014 Nov;111:42-52. doi: 10.1016/j.antiviral.2014.08.003. Epub 2014 Aug 13.

PMID:
25128688
21.

EVM005: an ectromelia-encoded protein with dual roles in NF-κB inhibition and virulence.

van Buuren N, Burles K, Schriewer J, Mehta N, Parker S, Buller RM, Barry M.

PLoS Pathog. 2014 Aug 14;10(8):e1004326. doi: 10.1371/journal.ppat.1004326. eCollection 2014 Aug.

22.

Initial characterization of vaccinia virus B4 suggests a role in virus spread.

Burles K, Irwin CR, Burton RL, Schriewer J, Evans DH, Buller RM, Barry M.

Virology. 2014 May;456-457:108-20. doi: 10.1016/j.virol.2014.03.019. Epub 2014 Apr 4.

23.

Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses.

Holechek SA, Denzler KL, Heck MC, Schriewer J, Buller RM, Legrand FA, Verardi PH, Jones LA, Yilma T, Jacobs BL.

PLoS One. 2013 Oct 17;8(10):e77879. doi: 10.1371/journal.pone.0077879. eCollection 2013.

24.

Immunoproteasome Activation During Early Antiviral Response in Mouse Pancreatic β-cells: New Insights into Auto-antigen Generation in Type I Diabetes?

Freudenburg W, Gautam M, Chakraborty P, James J, Richards J, Salvatori AS, Baldwin A, Schriewer J, Buller RM, Corbett JA, Skowyra D.

J Clin Cell Immunol. 2013 Apr 23;4(2). pii: 141.

25.
26.

RNA helicase signaling is critical for type i interferon production and protection against Rift Valley fever virus during mucosal challenge.

Ermler ME, Yerukhim E, Schriewer J, Schattgen S, Traylor Z, Wespiser AR, Caffrey DR, Chen ZJ, King CH, Gale M Jr, Colonna M, Fitzgerald KA, Buller RM, Hise AG.

J Virol. 2013 May;87(9):4846-60. doi: 10.1128/JVI.01997-12. Epub 2013 Feb 13.

27.

Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNβ in mouse pancreatic β-cells.

Freudenburg W, Gautam M, Chakraborty P, James J, Richards J, Salvatori AS, Baldwin A, Schriewer J, Buller RM, Corbett JA, Skowyra D.

PLoS One. 2013;8(2):e52408. doi: 10.1371/journal.pone.0052408. Epub 2013 Feb 1.

28.

Soft-X-ray-enhanced electrostatic precipitation for protection against inhalable allergens, ultrafine particles, and microbial infections.

Kettleson EM, Schriewer JM, Buller RM, Biswas P.

Appl Environ Microbiol. 2013 Feb;79(4):1333-41. doi: 10.1128/AEM.02897-12. Epub 2012 Dec 21.

29.

Oncolytic viruses.

Chen NG, Szalay AA, Buller RM, Lauer UM.

Adv Virol. 2012;2012:320206. doi: 10.1155/2012/320206. Epub 2012 Jun 6. No abstract available.

30.

Mousepox, a small animal model of smallpox.

Esteban D, Parker S, Schriewer J, Hartzler H, Buller RM.

Methods Mol Biol. 2012;890:177-98. doi: 10.1007/978-1-61779-876-4_11.

PMID:
22688768
31.

Ccr5 regulates inflammatory gene expression in response to encephalomyocarditis virus infection.

Christmann BS, Moran JM, McGraw JA, Buller RM, Corbett JA.

Am J Pathol. 2011 Dec;179(6):2941-51. doi: 10.1016/j.ajpath.2011.08.012. Epub 2011 Oct 11.

32.

Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.

Parker S, Siddiqui AM, Painter G, Schriewer J, Buller RM.

Viruses. 2010 Sep;2(9):1918-32. doi: 10.3390/v2091918. Epub 2010 Sep 3.

33.

The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.

Denzler KL, Schriewer J, Parker S, Werner C, Hartzler H, Hembrador E, Huynh T, Holechek S, Buller RM, Jacobs BL.

Vaccine. 2011 Dec 6;29(52):9691-6. doi: 10.1016/j.vaccine.2011.09.108. Epub 2011 Oct 5.

34.

The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses.

Melo-Silva CR, Tscharke DC, Lobigs M, Koskinen A, Wong YC, Buller RM, Müllbacher A, Regner M.

J Virol. 2011 Nov;85(21):11170-82. doi: 10.1128/JVI.00256-11. Epub 2011 Aug 17.

35.

Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.

Ruiz J, Beadle JR, Buller RM, Schreiwer J, Prichard MN, Keith KA, Lewis KC, Hostetler KY.

Bioorg Med Chem. 2011 May 1;19(9):2950-8. doi: 10.1016/j.bmc.2011.03.034. Epub 2011 Mar 23.

36.

2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members.

Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, Lin TY, Schneller S, Zust R, Dong H, Thiel V, Sen GC, Fensterl V, Klimstra WB, Pierson TC, Buller RM, Gale M Jr, Shi PY, Diamond MS.

Nature. 2010 Nov 18;468(7322):452-6. doi: 10.1038/nature09489.

37.

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Chen N, Bellone CJ, Schriewer J, Owens G, Fredrickson T, Parker S, Buller RM.

Virology. 2011 Jan 20;409(2):328-37. doi: 10.1016/j.virol.2010.10.021. Epub 2010 Nov 10.

38.

VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.

Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, Martin W, De Groot AS.

Vaccine. 2011 Jan 10;29(3):501-11. doi: 10.1016/j.vaccine.2010.10.064. Epub 2010 Nov 4.

39.

Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.

Moulton EA, Bertram P, Chen N, Buller RM, Atkinson JP.

J Virol. 2010 Sep;84(18):9128-39. doi: 10.1128/JVI.02677-09. Epub 2010 Jul 7.

40.

Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesis.

McNulty S, Bornmann W, Schriewer J, Werner C, Smith SK, Olson VA, Damon IK, Buller RM, Heuser J, Kalman D.

PLoS One. 2010 May 28;5(5):e10884. doi: 10.1371/journal.pone.0010884.

41.

Src family kinases participate in the regulation of encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages.

Freudenburg W, Buller RM, Corbett JA.

J Gen Virol. 2010 Sep;91(Pt 9):2278-85. doi: 10.1099/vir.0.022665-0. Epub 2010 May 26.

42.

Phosphatidylinositol 3-kinase regulates macrophage responses to double-stranded RNA and encephalomyocarditis virus.

Freudenburg W, Moran JM, Lents NH, Baldassare JJ, Buller RM, Corbett JA.

J Innate Immun. 2010;2(1):77-86. doi: 10.1159/000243785. Epub 2009 Oct 1.

43.

A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.

Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S.

J Virol. 2010 Apr;84(8):3909-20. doi: 10.1128/JVI.02012-09. Epub 2010 Feb 3.

44.

Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses.

Valiaeva N, Prichard MN, Buller RM, Beadle JR, Hartline CB, Keith KA, Schriewer J, Trahan J, Hostetler KY.

Antiviral Res. 2009 Dec;84(3):254-9. doi: 10.1016/j.antiviral.2009.09.012. Epub 2009 Oct 1.

45.

Therapeutic and prophylactic drugs to treat orthopoxvirus infections.

Parker S, Handley L, Buller RM.

Future Virol. 2008 Nov;3(6):595-612.

46.

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, Monsurró V, Buller RM, Stroncek DF, Wang E, Szalay AA, Marincola FM.

BMC Genomics. 2009 Jul 7;10:301. doi: 10.1186/1471-2164-10-301.

47.

The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.

Handley L, Buller RM, Frey SE, Bellone C, Parker S.

Expert Rev Vaccines. 2009 Jul;8(7):841-50. doi: 10.1586/erv.09.55. Review.

PMID:
19538111
48.

Surviving mousepox infection requires the complement system.

Moulton EA, Atkinson JP, Buller RM.

PLoS Pathog. 2008 Dec;4(12):e1000249. doi: 10.1371/journal.ppat.1000249. Epub 2008 Dec 26.

49.

Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.

Parker S, Siddiqui AM, Oberle C, Hembrador E, Lanier R, Painter G, Robertson A, Buller RM.

Virology. 2009 Mar 1;385(1):11-21. doi: 10.1016/j.virol.2008.11.015. Epub 2008 Dec 18.

50.

Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G, Buller RM.

Antivir Ther. 2008;13(7):863-73.

Supplemental Content

Loading ...
Support Center